The establishment of a credit evaluation system for 2 years, how to better play a role?

The National Organization Pharmaceutical Cooperative Purchasing Office issued the "National Pharmaceutical Pharmaceutical Procurement Documents (GY-YD2022-1)" announcement, officially launched the seventh batch of national drug collection and mining work, and will be opened on July 12.

The national collection has been added to the regional and alternative enterprises in terms of rules. In addition to choosing a middle -elected area, drug companies must also choose to prepare for the region. And this rule also associates with the medical price and recruitment credit evaluation system, that is, if the company is proposed to be rated as "serious" or "particularly serious" in the province If the selection varieties in the centralized procurement of drugs are disqualified from the joint procurement office, they do not have the qualifications for the first time to confirm the region for the first time to confirm the region.

Medicine prices and recruitment credit evaluation systems are playing an increasingly important role in the collection of medicines.

Medical prices and recruitment credit evaluation systems are the basic system of centralized procurement markets for drugs and medical consumables. It is of great significance to regulate market behavior, purify the trading environment, and protect the interests of the masses. In August 2020, the National Medical Insurance Bureau issued the "Guiding Opinions on Establishing a Medical Price and Recruitment Credit Evaluation System", proposed to establish a list of credit evaluation catalogs, implement the active commitment system of pharmaceutical companies, establish a channel for recording of credit information reports, and develop medical enterprise credit credit. 6 items such as rating. Since the implementation of the system, it has formulated prices for guiding and regulating the centralized procurement market for pharmaceutical products and promoting pharmaceutical companies in accordance with the principle of "fairness, reasonableness, and honesty, and quality and price.

Now that this document has been released, two years have passed, and the overall progress has been smooth. Not only has the establishment of the system in various provinces, but also in some areas have made substantial progress. The behavior carried out credit rating and hierarchical disposal.

Credit evaluation has made substantial progress in some areas of the country in the country

The "Guiding Opinions on the Establishment of Medicine Price and Recruitment Credit Evaluation System" requires that provincial -provincial and medical centralized procurement agencies are required to comprehensively establish a medical price and recruitment credit evaluation system. According to statistics from the National Medical Insurance Bureau's pharmaceutical price and bidding procurement guidance center, as of January 2021, all provinces, autonomous regions, municipalities, and Xinjiang Production and Construction Corps have all formulated specific policies to implement the credit evaluation system, publicized the list of credit items and credit evaluation operations Specifications and tailoring benchmarks.

After the establishment of a credit evaluation system for the price recruitment, the State Medical Insurance Bureau has promoted the implementation of integrated institutions at all levels in a timely manner. In accordance with the principles of territory, centralized procurement institutions are required to pay close attention to the decision of referee documents and administrative penalties publicly publicly publicized by courts, taxation, and market supervision departments in the regional courts, especially the typical cases reported by the media centralized reports. Get substantial governance results in credit rating and hierarchical disposal as soon as possible.

The first national credit evaluation of the governance of the "serious" level of governance occurred in Zhejiang Province in April 2021, marking that the price recruitment credit evaluation system has entered a new stage of exerting substantial effects. In this case, the Luguyan peptide injection of Harbin Yuheng Pharmaceutical Co., Ltd. has a commercial bribery behavior given to the deduction in Zhejiang Province. "Severe" and was suspended from the company's Lugua polypeptide injection in Zhejiang Province.

At present, all provinces have conducted credit evaluations on companies that have dishonesty in the area of ​​the area in accordance with the price of the province in accordance with the price of the province, and make a written reminder, restricting or suspending related product hanging or procurement in accordance with the regulations, etc. Essence Some pharmaceutical companies have also adopted measures such as active price cuts to repair credit.

Pharmaceutical business bribery and collection and breaking supply are the "severe disaster areas" in the disaster

The "Price Recruitment Credit Evaluation" column of the National Medical Insurance Bureau announced "serious" and "particularly serious" companies that broke their trust in order to strengthen social supervision and increase warning. As of now, the National Medical Insurance Administration has issued two phases to recruit credit evaluation "serious" and "particularly serious" dishonesty assessment results, involving 11 companies.

Note 1: Sichuan Zhitong Pharmaceutical Co., Ltd. has given recovery or improper interests at the former Aba Prefecture People's Hospital and the former Aba Prefecture Tibetan Hospital, involving the amount of 450,000 yuan and 710,000 yuan, respectively.

According to the "Pharmaceutical Price and Recruitment Trust Item List (2020 Edition)" issued by the State Medical Insurance Bureau, the dishonesty of the list of directory lists mainly includes giving rebates or other improper benefits in pharmaceutical purchase and sale (referred to as "medical commercial bribery") , Taxation illegal, the implementation of monopoly behaviors, improper price behaviors, disturbing centralized procurement order, malicious violations of contracts, etc. are contrary to honesty and trustworthy. Judging from the "severe" and "particularly serious" broom companies released by the State Medical Insurance Bureau, pharmaceutical commercial bribery and collection of contracts violated the contract is the "hardest hit area" for the current bidding and purchasing dishonesty. The former is the focus of correction in the field of medical purchase and sales. In the past two years, it has attracted much attention from social and related departments; the latter has a significant impact on the implementation effect of the collection of collection and land. Focus on behaviors that strive for avoidance.

The seventh batch of Credit Evaluation of China Cai will affect the selection of supply areas to effectively restrain the performance of enterprises for bribery and shortage of supply. The centralized procurement of drugs in the country has gradually introduced the price recruitment credit evaluation mechanism to bring the credit evaluation results and product declarations and product declarations. Council of qualifications, election rankings, and market allocation results, effectively constraints through the realization of credit evaluation with corporate interests.

The fifth batch of national concentrated band purchases for the first time quoted the credit evaluation system. First of all, adding "not being included in the current" National Pharmaceutical Price and Recruitment of Risk Warning List "in the qualifications of the application for enterprises; secondly At the same time, companies that have not been rated by any province based on medical prices and recruitment credit evaluation systems as "medium", "serious" or "particularly serious" enterprises priority; third, it is clear The recruitment credit evaluation system is rated as "serious" or "particularly serious" the level of dishonesty, and the province can refuse the Chinese -elected enterprise.

The seventh batch of national centralized band volume procurement has further increased the application strength and intensity of the credit evaluation system. If the proposed enterprise is evaluated by any province to be rated as "severe" or "particularly serious" the level of dishonesty in accordance with the medical price and recruitment credit evaluation system, or in two years Those who have been canceled by the joint procurement office will not be qualified for the first time to confirm the region, that is, a relatively missing region is not available in the confirmation of the main supply and preparation area, that is, a relatively missing region.

Jiang Changsong, director of the Medical Price and Tendering Purchasing Research Office of the National Medical Security Research Institute of the Capital Medical University, believes that in the future, the credit evaluation and performance will be integrated into the main links of the collection and continuation rules, so that they will be qualified for corporate declarations, comprehensive scores, and comprehensive scores. Election qualifications, election positions, and supply areas to play a substantial role in the selection of supply areas. For example, in the previous round of selected companies, such as the results of the comprehensive evaluation or credit, and the performance of the contract, they can be given priority in the continuation work; if the credit and performance are poor, punishment should be punished in the continuation rules. If the application for the joint procurement office of the National Organization of Drugs is included in the "illegal list" or the province is identified as the dishonesty to varying degrees, it can take the disposal measures such as the election position, the proportion of the band, and the reduction of the supply area in accordance with the regulations. Suspension its qualifications to participate.

- END -